Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies
Clinical trial NCT05164458 · UNKNOWN
Trial details
- NCT number
- NCT05164458
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-22
- Primary completion
- 2024-04-30
- Enrollment
- 320
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.